Ocular Therapeutix Reports Strong SOL-1 Data, Accelerates AXPAXLI NDA Submission
Event summary
- Ocular Therapeutix reported positive Phase 3 SOL-1 trial results for AXPAXLI in wet AMD, demonstrating superiority over aflibercept.
- Company plans to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing FDA discussions.
- SOL-R Phase 3 trial on track for topline readout in 1Q 2027, with SOL-X extension trial enrollment underway.
- Cash balance of $666.7 million as of March 31, 2026, with runway into 2028.
The big picture
Ocular Therapeutix's positive SOL-1 trial results position AXPAXLI as a potential game-changer in the treatment of wet AMD, offering superior durability and disease control compared to existing therapies. The company's strategic focus on accelerating the NDA submission and preparing for commercialization reflects its confidence in AXPAXLI's market potential. The biopharmaceutical industry is increasingly focused on developing long-lasting treatments for retinal diseases, and Ocular Therapeutix's progress could set a new standard for wet AMD therapy.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the NDA submission based on SOL-1 Week 52 data and the potential time savings from the 505(b)(2) pathway.
- Commercial Readiness
- The pace at which Ocular Therapeutix can prepare for commercialization if AXPAXLI receives approval.
- Clinical Trial Outcomes
- The results of the SOL-R and HELIOS-3 trials, which will further validate AXPAXLI's efficacy and expand its potential market.